Nanobiotix (NASDAQ:NBTX) Stock Price Up 4.6% – Still a Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) traded up 4.6% during mid-day trading on Thursday . The company traded as high as $38.81 and last traded at $38.3330. Approximately 168,499 shares changed hands during trading, an increase of 96% from the average daily volume of 86,095 shares. The stock had previously closed at $36.64.

Wall Street Analyst Weigh In

Several analysts recently commented on NBTX shares. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners upped their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Down 1.6%

The firm’s fifty day moving average is $39.69 and its 200 day moving average is $37.05.

Institutional Trading of Nanobiotix

Institutional investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Millennium Management LLC acquired a new stake in Nanobiotix in the 4th quarter worth about $390,000. Finally, Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter worth approximately $220,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.